Physician profile
Tamara E Patterson
NPI 1720350580
$2,086.21
in general payments reported to CMS, 2019-2025
27 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.58 · 2022: $391 · 2023: $330 · 2024: $783 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.78 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.94 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $180.29 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $151.40 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Convatec INC. | $132.95 | 2024 | |
| Merck Sharp & Dohme LLC | $119.24 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Lilly USA, LLC | $117.73 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $103.47 | 2023-2025 | |
| Amgen INC. | $97.38 | 2022-2024 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $88.56 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.95 | 2021-2025 | Jardiance |
| Insulet Corporation | $73.33 | 2024 | Omnipod |
| Biohaven Pharmaceutical Holding Company Ltd. | $62.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $45.91 | 2023 | Quviviq |
| Dexcom, INC. | $44.17 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $43.16 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $27.13 | 2025 | Korlym |
| Cequr Corporation | $22.13 | 2024 | Cequr Simplicity |
| Viatris Specialty LLC | $20.05 | 2025 | Yupelri |
| Ironshore Pharmaceuticals INC. | $17.03 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $15.98 | 2023 | Austedo |
| Novartis Pharmaceuticals Corporation | $15.50 | 2024 | |
| Boston Scientific Corporation | $13.42 | 2022 | |
| Agios Pharmaceuticals, INC. | $13.23 | 2023 | Pyrukynd |
| Sanofi Pasteur INC. | $12.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.